Toepfer M, Schlosshauer M, Sitter T, Burchardi C, Behr T, Schiffl H
Department of Nephrology, Medizinische Klinik, Klinikum Innenstadt Ludwig Maximillians University, Munich, Germany.
Blood Purif. 1998;16(5):269-74. doi: 10.1159/000014344.
To characterize the determinants of circulating levels of adrenomedullin (AM), the plasma levels of this peptide were measured in 58 patients with end-stage renal disease on hemodialysis. Predialysis plasma levels of AM were more than twice as high in patients on hemodialysis as compared to controls. In hemodialysis patients with heart failure (NYHA classes II-IV) or hypertensive HD patients plasma levels of AM were significantly higher than in patients with end-stage renal disease only. Plasma levels of AM were not altered immediately by hemodialysis but decreased significantly 14-20 h after hemodialysis. AM plasma levels before hemodialysis and 14-20 h after hemodialysis were correlated with the corresponding mean arterial pressure.
为了明确肾上腺髓质素（AM）循环水平的决定因素，我们对58例接受血液透析的终末期肾病患者的血浆中该肽水平进行了测定。与对照组相比，接受血液透析患者的透析前血浆AM水平高出两倍多。在伴有心力衰竭（纽约心脏协会II-IV级）的血液透析患者或高血压血液透析患者中，AM的血浆水平显著高于仅患有终末期肾病的患者。血液透析不会立即改变AM的血浆水平，但在透析后14 - 20小时会显著降低。透析前和透析后14 - 20小时的AM血浆水平与相应的平均动脉压相关。
